Miguel is a Senior Research Investigator at Isomorphic Labs, where he leads the biological strategy for drug discovery programs in oncology and immunology. He holds a Pharmacy degree from the University of Murcia and an MSc in Cancer Pharmacology from London Metropolitan University. After early structural biology research using Cryo-EM at the Francis Crick Institute, he spent several years at AstraZeneca, advancing to Senior Scientist in Protein Science and project leadership in Oncology. He later served as a Biology Project Lead at BenevolentAI, directing AI-driven discovery workflows. At Isomorphic Labs, Miguel work leads the biological strategy of drug discovery programs and collaborates with multidisciplinary teams to harness the power of AlphaFold—recognized with the 2024 Nobel Prize in Chemistry—and develop next-generation technologies to transform modern medicine design.
